A pivotal trial, PRIMARY study, demonstrated that the addition of PSMA PET to MRI resulted in improved sensitivity (97% for combined vs. 83% for MRI alone) and negative predictive value (91% for combined vs. 72% for MRI alone) for clinically significant prostate cancer in a MRI triaged patient population [32]. This evidence concerns the gene FOLH1 and prostate cancer.